SLCO1B3 and chronic myelogenous leukemia, BCR-ABL1 positive: In a recently reported screen of FDA-approved TKIs, we found that nilotinib, an inhibitor of the Bcr-Abl tyrosine kinase used for the treatment of patients with chronic myeloid leukemia, was the most potent inhibitor of OATP1B2 and OATP1B3 (55), in line with several recent reports (54, 56).